Cholinesterase inhibitors for Alzheimer's disease

Drugs

Volumn 61, Issue 1, 2001, Pages 41-52

  Grutzendler, J ^a   Morris, J C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; METRIFONATE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; BEHAVIOR; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; MOOD; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

EID: 0035142278     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161010-00005     Document Type: Review

References (75)

1. Estimated prevalence of Alzheimer's disease in the United States
2. The US economic and social costs of Alzheimer's disease revisited
3. An update on primary drug therapies for Alzheimer disease
4. Alzheimer's disease: Genotypes, phenotypes, and treatments
5. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
6. The presenilins in Alzheimer's disease: Proteolysis holds the key
7. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
8. Alzheimer neurofibrillary lesions: Molecular nature and potential roles of different components
9. Mechanisms of synaptic dysfunction in Alzheimer's disease
10. Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
11. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
12. Alzheimer's disease: A disorder of cortical cholinergic innervation
13. Brain choline acetyltransferase and mental function in Alzheimer disease
14. Possible role of the cholinergic system and disease models
15. Cholinergic markers in elderly patients with early signs of Alzheimer disease
16. Muscarinic agonist therapy of Alzheimer's disease: A clinical trial of RS-86
17. No response to high-dose muscarinic agonist therapy in Alzheimer's disease
18. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
19. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease
20. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
21. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines
22. NGF promotes amyloid precursor protein secretion via muscarinic receptor activation
23. Pharmacology and clinical efficacy of cholinesterase inhibitors
24. A controlled trial of latrine in Alzheimer's disease: The Tacrine Study Group
25. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease: The Tacrine Collaborative Study Group
26. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease: The Tacrine Study Group
27. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease
28. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
29. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
30. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease
31. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
32. Donepezil improves symptoms of delirium in dementia: Implications for future research
33. The spectrum of behavioural responses to cholinesterase inhibitor therapy in Alzheimer disease
34. Cholinesterase inhibitors: A new class of psychotropic compounds
35. Second and third generation cholinesterase inhibitors: From preclinical studies to clinical efficacy
36. 'Mini-mental state': A practical method for grading the cognitive state of patients for the clinician
37. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
38. Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a one-year placebo-controlled functional survival study
39. Metabolism and elimination of 14C-donepezil in healthy volunteers: A single-dose study
40. Concurrent administration of donepezil HCl and cimetifine: Assessment of pharmacokinetic changes following single and multiple doses
41. Tacrine may prolong the effect of succinylcholine
42. Inhibition of tacrine oral clearance by cimetidine
43. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease
44. Safety of tacrine: Clinical trials, treatment IND, and postmarketing experience
45. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease
46. The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease
47. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease
48. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses
49. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil Study Group
50. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study
51. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease
52. Retina, brain and blood cholinesterase levels in cats treated with oral dichlorvos
53. Treatment of Alzheimer's disease
54. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease
55. Galanthamine, a selective nontoxic acetylchotinesterase inhibitor is significantly superior over placebo in the treatment of SDAT
56. Clinical studies of galanthamine
57. A 5-month, randomised, placebo-contolled trial with a 6-month extension: The Galantamine USA- I Study Group
58. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
59. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
60. Treatment of Alzheimer disease with tacrine: A cost-analysis model
61. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada
62. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
63. Risk of Alzheimer's disease and duration of NSAID use
64. A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer's disease: The Alzheimer's Disease Cooperative Study
65. Neuroprotection by estradiol
66. Estrogen as a treatment for Alzheimer's disease
67. A randomized controlled trial of prednisone in Alzheimer's disease: Alzheimer's Disease Cooperative Study
68. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial
69. Combination therapy for early Alzheimer's disease: What are we waiting for?
70. Emerging antidementia drugs: A preliminary ethical view
71. Clinical trials in Alzheimer disease: Debate on the use of placebo controls
72. Do we have a treatment for Alzheimer disease? Yes
73. Do we have drugs for dementia? No
74. Tacrine use in nursing homes: Implications for prescribing new cholinesterase inhibitors